Hepatocellular Carcinoma Non-resectable Clinical Trial
Official title:
Efficacy and Safety of the Combination of Transarterial Therapies With Donafenib Plus Anti-PD-1 Antibody for Unresectable Hepatocellular Carcinoma: A Retrospective Real-world Study
This Retrospective Real-world study was designed to evaluate the clinical efficacy and safety of the Combination of transarterial therapies with donafenib plus Anti-PD-1 Antibody for Unresectable Hepatocellular Carcinoma.
Data of Patients who have received Triplet therapy ( transarterial therapies+donafenib+Anti-PD-1 Antibody）will be collected，excluding incomplete data. The primary endpoint was the objective response rate (ORR)，Secondary endpoints included disease control rate (DCR), progression-free survival rate (PFSR) [ Time Frame: 6- and 12-month], overall survival rate (OSR) [ Time Frame: 6- and 12-month], the median progression-free survival time (mPFS) and median overall survival time (mOS)， as well as adverse event. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04592029 -
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
|
Phase 1 | |
| Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
| Not yet recruiting |
NCT03283956 -
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
|
N/A | |
| Recruiting |
NCT03652467 -
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05031949 -
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT03533920 -
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Not yet recruiting |
NCT05057104 -
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
|
||
| Completed |
NCT04599777 -
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
|
Phase 2 | |
| Completed |
NCT04599790 -
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT02967887 -
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
|
Phase 2 | |
| Recruiting |
NCT05608200 -
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
|
Phase 3 | |
| Recruiting |
NCT05608213 -
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
|
Phase 3 | |
| Completed |
NCT04926376 -
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC
|
N/A | |
| Recruiting |
NCT06133062 -
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT02989922 -
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT04273100 -
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
|
Phase 2 | |
| Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
| Recruiting |
NCT05713994 -
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
|